EyePoint Misses Primary Endpoint in Phase 3 Trial But Sees Promise After Analysis

Eyepoint Pharmaceuticals releases key phase 3 data for its wet AMD drug Duravyu; Zeiss receives FDA clearance for a cloud- and browser-based data management solution; and the FDA expands Sight Sciences’ indications for the TearCare System for the treatment of MGD. Learn more about your ad choices. Visit megaphone.fm/adchoices